Drug Profile
Poloxamer 188 - LadRx Corporation
Alternative Names: RheothRxLatest Information Update: 29 Sep 2022
Price :
$50
*
At a glance
- Originator CytRx Corporation
- Class Anti-inflammatories; Antithrombotics; Cytoprotectives; Polyethylene glycols; Surfactants
- Mechanism of Action Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Burns; Cancer; Malaria; Myocardial infarction; Respiratory distress syndrome; Stroke; Thrombosis
Most Recent Events
- 23 Sep 2022 CytRx Corporation is now called LadRx Corporation
- 27 Sep 2000 Discontinued-II for Respiratory distress syndrome in USA (Parenteral)
- 27 Sep 2000 Discontinued-II for Stroke in USA (Parenteral)